Predicting sustained virological response in chronic hep C therapy

[Guest guest]

Predicting sustained virological response in chronic hep C therapy

Predicting sustained virological response in chronic hep C therapy A study in the recently published Journal of Viral Hepatitis estimates the likelihood of sustained virological response in chronic hepatitis C therapy.The likelihood of a sustained virological response is the most important factor for physicians and patients in the decision to initiate and continue therapy for chronic hepatitis C infection. Dr Stefan Mauss and colleagues from Germany identified predictive factors for sustained virological response with peginterferon plus ribavirin in patients with chronic hepatitis C treated under ‘real-life’ conditions. The study cohort consisted of patients from a large, retrospective German multicentre, observational study who had been treated with peginterferon alfa-2a plus RBV or peginterferon alfa-2b plus ribavirin

between the years 2000 and 2007. To ensure comparability regarding peginterferon therapies, patients were analyzed in pairs matched by several baseline variables. Sustained virological response rates were 58% overall Journal of Viral Hepatitis The researchers determined the effect of nonmatched baseline variables and treatment modality on sustained virological response. Among 2378 patients, sustained virological response rates were 58% overall, 47% in HCV genotype 1/4-infected patients and 77% in genotype 2/3-infected patients. In multivariate logistic regression analysis, positive predictors of sustained virological response were HCV genotype 2 infection, HCV genotype 3 infection, low baseline viral load and treatment with peginterferon alfa-2a. The research team found that the negative predictors of sustained virological response were higher age, elevated baseline gamma-glutamyl transpeptidase and low

baseline platelet count. Dr Mauss' team commented, "Among patients treated with peginterferon plus ribavirin in routine clinical practice, genotype, baseline viral load, age, gamma-glutamyl transpeptidase level and platelet levels all predict the likelihood of treatment success." "In patients matched by baseline characteristics, treatment with peginterferon alfa-2a may be a positive predictor of sustained virological response when compared to peginterferon alfa-2b."http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01372.x/abstract

http://Hepatitis Cnewdrugs.blogspot.com/2011/04/predicting-sustained-virological.html